1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,490 | 0,530 | 03.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.02. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 29.01. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 10.01. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| PROTAGENIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 20.12.24 | Protagenic Therapeutics files to sell 5.84M shares | 5 | Seeking Alpha | ||
| 20.12.24 | Protagenic Therapeutics, Inc.\new - S-1, General form for registration of securities | - | SEC Filings | ||
| 03.12.24 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 22.11.24 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 05.11.24 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million | 388 | ACCESS Newswire | NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today that... ► Artikel lesen | |
| 05.11.24 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 1 | SEC Filings | ||
| 29.10.24 | Protagenic Therapeutics announces $1.275 million stock sale | 3 | Investing.com | ||
| 29.10.24 | Protagonist Therapeutics: Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million | 315 | ACCESS Newswire | NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it... ► Artikel lesen | |
| 18.09.24 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 22.05.24 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychi | 319 | ACCESS Newswire | No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to CommenceInvestor Call Scheduled for today, Wednesday, May 22, at 10:00 am ET to Discuss Potential Impact... ► Artikel lesen | |
| 01.05.24 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial | 633 | ACCESS Newswire | NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion... ► Artikel lesen | |
| 17.04.24 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit | 586 | ACCESS Newswire | Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical... ► Artikel lesen | |
| 01.04.24 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results | 343 | ACCESS Newswire | Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized... ► Artikel lesen | |
| 27.03.24 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders | 303 | ACCESS Newswire | Next clinical progress update expected in April 2024NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mission... ► Artikel lesen | |
| 25.03.24 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call | 425 | ACCESS Newswire | Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ETNEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company... ► Artikel lesen | |
| 21.03.24 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice | 312 | ACCESS Newswire | NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 2,954 | +0,68 % | CureVac Aktie: Kreativ und erfolgreich | Die CureVac-Aktie zeigte am Donnerstag eine durchgehend negative Tendenz im Tradegate-Handel. Bereits zum Handelsstart notierte der Anteilsschein bei 3,03 EUR und rutschte im Tagesverlauf weiter ab.... ► Artikel lesen | |
| VALNEVA | 3,372 | -0,94 % | Valneva-Aktie: Höhenflug erstmal zu Ende? | Die Valneva-Aktie hat in diesem Jahr eine fulminante Kursexplosion erlebt. Doch am heutigen Dienstag verliert sie kräftig auf aktuell 3,76 €. Ist der Höhenflug jetzt erstmal zu Ende? Analyst optimistisch... ► Artikel lesen | |
| BIOFRONTERA | 2,265 | -2,79 % | Top-Zock 2025: Formycon, Biofrontera oder BB Biotech? | Auf der Suche nach unserem Top-Zock 2025 haben wir unzählige Small- und Nano-Cap-Titel analysiert. Ein Wert sticht dabei mit einem überragenden Chance-Risiko-Profil über die nächsten Monate heraus.... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,849 | +3,16 % | Palatin Technologies Inc. Q2 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) revealed Loss for second quarter that decreased from the same period last year and beat the Street estimates.The company's earnings came... ► Artikel lesen | |
| BIOXXMED | 0,832 | -7,56 % | EQS-Adhoc: bioXXmed AG: bioXXmed beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | EQS-Ad-hoc: bioXXmed AG / Schlagwort(e): Sonstiges
bioXXmed AG beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts
21.02.2025 / 20:29 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| ORGANOVO | 0,688 | +1,47 % | Organovo, Inc.: Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company | SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,800 | +2,27 % | INOVIO Pharmaceuticals, Inc.: Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications | Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by... ► Artikel lesen | |
| OCUGEN | 0,581 | +0,26 % | Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease | MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,859 | -2,73 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile | Sustained benefit demonstrated with elevated expression of alpha-galactosidase A (a-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date Positive... ► Artikel lesen | |
| INFLARX | 1,200 | +1,01 % | InflaRx N.V.: InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting | ||
| SIRONA BIOCHEM | 0,037 | -2,67 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,490 | -0,12 % | Viking Therapeutics Aktie: Einholung von Informationen | Viking Therapeutics befindet sich an einem entscheidenden Punkt, während der Biotechsektor auf ein dynamisches Jahr zusteuert. Die Aktie des Unternehmens brach am Montag um 11,75 Prozent auf 24,49 Euro... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 9,080 | +0,75 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress | Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics... ► Artikel lesen | |
| BIO-GATE | 0,755 | -3,82 % | EQS-News: Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhält in klinischer Studie Testergebnis "sehr gut" | EQS-News: Bio-Gate AG
/ Schlagwort(e): Studienergebnisse/Sonstiges
Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhält in klinischer Studie Testergebnis "sehr... ► Artikel lesen | |
| EDITAS MEDICINE | 1,731 | +2,76 % | Editas Medicine, Inc.: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities | Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia... ► Artikel lesen |
Das Unternehmen PROTAGENIC THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -100,00 % bei einem Aktienkurs von 0,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROTAGENIC THERAPEUTICS INC finden Sie auf Wallstreet Online.
